Increased urinary losses of carnitine during ifosfamide chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 2, 1999, Pages 170-172

  Marthaler, Niklaus P ^a   Visarius, Theresa ^a   Küpfer, Adrian ^a   Lauterburg, Bernhard H ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Carnitine; Ifosfamide; Urinary excretion

Indexed keywords

CARNITINE; CHLOROACETALDEHYDE; GLYCOLIC ACID DERIVATIVE; IFOSFAMIDE; THIODIACETIC ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARNITINE DEFICIENCY; CLINICAL ARTICLE; CONTINUOUS INFUSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TUBULE ABSORPTION; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; URINARY EXCRETION;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; CARNITINE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED;

EID: 0033031334     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050963     Document Type: Article

References (15)

1. 1. Bremer J (1983) Carnitine - metabolism and functions. Physiol Rev 63: 1420
2. 2. Dechant KL, Brogden RN, Pilkington T, Faulds D (1991) Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 42: 428
3. 3. Dodson WL, Sachan DS, Krauss S, Hanna W (1989) Alterations of serum and urinary carnitine profiles in cancer patients: hypothesis of possible significance. J Am Coll Nutr 8: 133
4. 4. Heuberger W, Berardi S, Jacky E, Pey P, Krähenbühl S (1998) Increased urinary excretion of carnitine in patients treated with cisplatin. Eur J Clin Pharmacol 54: 503
5. 5. Keizer HJ, Ouwerkerk J, Welvaart K, Velde CJ van der, Cleton FJ (1995) Ifosfamide treatment as a 10-day continuous intravenous infusion. J Cancer Res Clin Oncol 121: 297
6. 6. Küpfer A, Aeschlimann C, Cerny T (1996) Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol 4: 249
7. 7. Pearson DJ, Tubbs PK, Chase JFA (1974) Carnitine and acylcarnitine. In: Bergmeyer HU (ed) Methoden der enzymatischen Analyse, 3rd edn. Verlag Chemie, Weinheim, p 1806
8. 8. Schlenzig JS, Charpentier C, Rabier D, Kamoun P, Sewell AC, Harpey JP (1995) L-Carnitine: a way to decrease cellular toxicity of ifosfamide? Eur J Pediatr 154: 686
9. 9. Skinner R, Sharkey IM, Pearson AD, Craft AW (1993) Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 11: 173
10. 10. Skinner R, Pearson ADJ, English MW, Price L, Wyllie RA, Coulthard MG, Craft AW (1996) Risk factors for ifosfamide nephrotoxicity in children. Lancet 348: 578
11. 11. Skrede S, Sorensen HN, Larsen LN, Steineger HH, Hovik K, Spydevold OS, Horn R, Bremer J (1997) Thia fatty acids, metabolism and metabolic effects. Biochim Biophys Acta 1344: 115
12. 12. Steinmann B, Bachmann C, Colombo JP, Gitzelmann R (1987) The renal handling of carnitine in patients with selective tubulopathy and with Fanconi syndrome. Pediatr Res 21: 201
13. 13. Visarius TM, Lauterburg BH, Küpfer A, Stucki JW (1996) Long chain fatty acid oxidation in mitochondria is inhibited by chloroacetaldehyde and restored by methylene blue. Experientia 52: A85
14. 14. Visarius TM, Stucki JW, Lauterburg BH (1997) Stimulation of respiration by methylene blue in rat liver mitochondria. FEBS Lett 412: 157
15. 15. Visarius TM, Bähler H, Küpfer A, Cerny T, Lauterburg BH (1998) Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats. Drug Metab Dispos 26: 193